Companies › Hangzhou DAC Biotechnology
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DXC006 Recombinant humanized antibody-drug conjugate | – | Phase 1 | Advanced Solid Tumors; Small Cell Lung Cancer | Jun 2027 |
| DEC003M | – | Phase 1 | Advanced Prostate Cancer | Mar 2029 |
| DXC008 | – | Phase 1 | Prostate Cancer | Apr 2030 |
| DXC014 | – | Phase 1 | Small Cell Lung Cancer | Oct 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06224855 | DXC006 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2027 |
| NCT07559929 | DXC006 | Phase 1 | Small Cell Lung Cancer | Oncology | Jun 2028 |
| NCT07657806 | DEC003M | Phase 1 | Advanced Prostate Cancer | Oncology | Mar 2029 |
| NCT06926283 | DXC008 | Phase 1 | Prostate Cancer | Oncology | Apr 2030 |
| NCT07177937 | DXC014 | Phase 1 | Small Cell Lung Cancer | Oncology | Oct 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.